Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC

 
• By Alaric DeArment
  
Amgen presented data at WCLC for its bispecific antibody, tarlatamab, in small-cell lung cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category